Overview of melanoma vaccines and promising approaches

Current Oncology Reports

Volumn 6, Issue 5, 2004, Pages 414-420

  Panelli, Monica C ^a   Wang, Ena ^a   Monsurrò, Vladia ^a   Jin, Ping ^a   Katia, Zavaglia ^a   Smith, Kina ^a   Ngalame, Yvonne ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CANVAXIN; GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELACINE; MELANOMA VACCINE; T LYMPHOCYTE RECEPTOR;

BIOTECHNOLOGY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EXPECTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MICROENVIRONMENT; PHENOTYPE; PREDICTION; PROTEIN EXPRESSION; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 4544291831     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0069-3     Document Type: Review

References (76)

1. Marincola FM, Wang E, Herlyn M, et al.: Tumors as elusive targets of T cell-directed immunotherapy. Trends Immunol 2003, 24:334-341.
2. Marincola FM, Ferrone S: Immunotherapy of melanoma: the good news, the bad news and what to do next. Semin Cancer Biol 2003, 13:387-389.
3. Parmiani G, Castelli C, Dalerba P, et al.: Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going? J Natl Cancer Inst 2002, 94:805-818.
4. Hsueh EC, Morton DL: Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003, 13:401-407.
5. Sondak VK, Sosman J: Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol 2003, 13:409-415.
6. Horig H, Kaufman HL: Local delivery of poxvirus vaccines for melanoma. Semin Cancer Biol 2003, 13:417-422.
7. Scheibenbogen C, Letsch A, Schmittel A, et al.: Rational peptide-based tumor vaccine development and T cell monitoring. Semin Cancer Biol 2003, 13:423-429.
8. Talebi T, Weber JS: Peptide vaccine trials for melanoma: pre-clinical background and clinical results. Semin Cancer Biol 2003, 13:431-438.
9. Paczesny S, Ueno H, Fay J, et al.: Dendritic cells as vectors for immunotherapy of cancer. Semin Cancer Biol 2003, 13:439-447.
10. Speiser DE, Pittet MJ, Rimoldi D, et al.: Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor specific T cells. Semin Cancer Biol 2003, 13:461-472.
11. Monsurro' V, Wang E, Panelli MC, et al.: Active-specific immunization against cancer: Is the problem at the receiving end? Semin Cancer Biol 2003, 13:473-480.
12. Curtsinger JM, Johnson CM, Mescher MF: CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol 2003, 171:5165-5171.
13. Kaech SM, Hemby S, Kersh E, Ahmed R: Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002, 111:837-851.
14. Wherry EJ, Teichgraber V, Becker TC, et al.: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nature Immunol 2003, 4:225-234.
15. Cuenca A, Cheng F, Wang H, et al.: Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 2003, 63:9007-9015.
16. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
17. Dunn GP, Bruce AT, Ikeda H, et al.: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
18. Khong HT, Restifo NP: Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002, 3:999-1005.
19. Tomaru U, Yamano Y, Nagai M, et al.: Detection of virus-specific T cells and CD8+ T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nat Med 2003, 9:469-476.
20. Rubio V, Stuge TB, Singh N, et al.: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003, 9:1377-1382.
21. Shafer-Weaver K, Sayers T, Strobl S, et al.: The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 2003, 1:14.
22. Malyguine A, Strobl S, Shafer-Weaver K, et al.: A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J Transl Med 2004, 2: 9.
23. Colaco CALS: Cancer immunotherapy: simply cell biology? Trends Mol Med 2003, 9:515-516.
24. Fuchs EJ, Matzinger P: Is cancer dangerous to the immune system? Semin Immunol 1996, 8:271-280.
25. Matzinger P: Danger model of immunity. Scand J Immunol 2001, 54:2-3.
26. Ochsenbeinh AF, Klenerman P, Karrer U, et al.: Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999, 96:2233-2238.
27. Monsurro' V, Wang E, Yamano Y, et al.: Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004, Jun 8 [Epub ahead of print].
28. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000, 74:181-273.
29. Wang E, Miller LD, Ohnmacht GA, et al.: Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002, 62:3581-3586.
30. Jin P, Wang E: Polymorphism in clinical immunology: from HLA typing to immunogenetic profiling. J Transl Med 2003, 1:8.
31. Ohnmacht GA, Wang E, Mocellin S, et al.: Short term kinetics of tumor antigen expression in response to vaccination. J Immunol 2001, 167:1809-1820.
32. Kammula US, Lee K-H, Riker A, et al.: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999, 163:6867-6879.
33. Panelli MC, Riker A, Kammula US, et al.: Expansion of tumor/T cell pairs from fine needle aspirates (FNA) of melanoma metastases. J Immunol 2000, 164:495-504.
34. Perez-Diez A, Spiess PJ, Restifo NP, et al.: Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol 2002, 168:338-347.
35. Monsurro' V, Nielsen M-B, Perez-Diez A, et al.: Kinetics of TCR use in response to repeated epitope-specific immunization. J Immunol 2001, 166:5817-5825.
36. Thor Straten P, Schrama DD, Andersen MH, Becker JC: T cell clonotypes in cancer. J Transl Med 2004, 2:11.
37. Zea AH, Curti BD, Longo DL, et al.: Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995, 1:1327-1335.
38. Lee PP, Yee C, Savage PA, et al.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999, 5:677-685.
39. Speiser DE, Colonna M, Ayyoub M, et al.: The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. J Immunol 2001, 167:6165-6170.
40. Nielsen M-B, Monsurro' V, Miguelse S, et al.: Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol 2000, 165:2287-2296.
41. Pittet MJ, Zippelius A, Speiser DE, et al.: Ex vivo IFN-g secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 2001, 166:7634-7640.
42. Appay V, Nixon DF, Donahoe SM, et al.: HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000, 192:63-75.
43. Hamann D, Baars PA, Rep MHG, et al.: Phenotype and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997, 186:1407-1418.
44. Sallusto F, Lenig D, Forster R, et al.: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:659-660.
45. Champagne P, Ogg GS, King A, et al.: Skewed maturation of memory HIV-specific CD8 T lymphoctes. Nature 2001, 410:106-111.
46. Monsurro' V, Nagorsen D, Wang E, et al.: Functional heterogeneity of vaccine-induced CD8+ T cells. J Immunol 2002, 168:5933-5942.
47. Migueles SA, Laborico AC, Shupert WL, et al.: HIV-specific CD8+ T cell proliferation is coupled to perforing expression and is maintained in nonprogressors. Nat Immunol 2002, 3:1061-1068.
48. van Baarle D, Kostense S, van Oers MHL, Miedema F: Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol 2002, 23:586-591.
49. Appay V, Dunbar PR, Callan M, et al.: Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002, 8:379-385.
50. Speiser DE, Lienard D, Pittet MJ, et al.: In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines: a comparison to virus-specific T cells. Eur J Immunol 2002, 32:731-741.
51. Lee K-H, Wang E, Nielsen M-B, et al.: Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999, 163:6292-6300.
52. Pittet MJ, Speiser DE, Lienard D, et al.: Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res 2001, 7:796s-803s.
53. Thurner B, Haendle I, Roder C, et al.: Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999, 190:1669-1678.
54. Scheibenbogen C, Schmittel A, Keilholz U, et al.: Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 2000, 23:275-281.
55. Boon T, Cerottini J-C, Van den Eynde B, et al.: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994, 12:337-365.
56. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997, 18:175-182.
57. Old LJ, Chen YT: New paths in human cancer serology. J Exp Med 1998, 187:1163-1167.
58. Marincola FM: Interleukin-2. Biol Ther Cancer Updates 1994, 4:1-16.
59. Rosenberg SA, Lotze MT, Yang JC, et al.: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989, 210:474-484.
60. Boon T, Coulie PG, Van den Eynde B: Tumor antigens recognized by T cells. Immunol Today 1997, 18:267-268.
61. Cormier JN, Salgaller ML, Prevette T, et al.: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997, 3:37-44.
62. Rosenberg SA, Yang JC, Schwartzentruber D, et al.: Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4:321-327.
63. Panelli MC, Wang E, Phan G, et al.: Genetic profiling of peripharal mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol 2001 3:RESEARCH0035.
64. Panelli MC, White R, Foster M, et al.: Forecasting the cytokine storm following systemic interleukin-2 administration. J Transl Med 2004, 2:17.
65. Panelli MC, Martin B, Nagorsen D, et al.: A genomic and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. Cell Tissues Organs, in press.
66. Pockaj BA, Sherry RM, Wei JP, et al.: Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response. Cancer 1994, 73:1731-1737.
67. Wolfel T, Klehmann E, Muller C, et al.: Lysis of human melanoma cells by autologolus cytolytic T cell clones: identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989, 170:797-810.
68. Mocellin S, Panelli MC, Wang E, et al.: The dual role of IL-10. Trends Immunol 2002, 24:36-43.
69. Wang E, Marincola FM: A natural history of melanoma: serial gene expression analysis. Immunol Today 2000, 21:619-623.
70. Wang E, Marincola FM, Stroncek D: Human leukocyte antigen (HLA) and human neutrophil antigen (HNA) systems. In Hematology: Basic Principles and Practice. Edited by Hoffman R, Benz EJ, Shattil SJ, et al. Philadelphia: Elsevier Science; in press.
71. Rubin JT, Adams SD, Simonis T, Lotze MT: HLA polymorphism and response to IL-2 bases therapy in patients with melanoma. Proc Soc Biol Ther Annu Meet 1991, 1:18.
72. Marincola FM, Shamamian P, Rivoltini L, et al.: HLA associations in the anti-tumor response against malignant melanoma. J Immunother 1996, 18:242-252.
73. Lee JE, Reveille JD, Ross MI, Platsoucas CD: HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 1994, 59:510-51.
74. Howell WM, Bateman AC, Turner SJ, et al.: Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 2002, 3:229-232.
75. Howell WM, Calder PC, Grimble RF: Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc 2002, 61:447-456.
76. Wang E, Adams S, Zhao Y, Panelli MC, Simon R, Klein H et al.: A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides. J Transl Med 2003, 1:4.